AstraZeneca

132 articles with AstraZeneca

• DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast Cancer

  6/14/2021

  DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU ® Initiated in Patients with HER2 Positive Metastatic Breast Cancer.

• IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years

  6/4/2021

  IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years

• LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial

  6/3/2021

  AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA®

• AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience

  5/19/2021

  LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib

• 

  Monoclonal Antibody Proves Worth in Asthma Study

  5/13/2021

  Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma. 

• IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer

  5/7/2021

  IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer First Phase III trial to demonstrate overall survival benefit with tremelimumab IMFINZI plus chemotherapy demonstrated progression-free survival benefit, but a trend in overall survival did not achieve statistical significance

• Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center

  4/27/2021

  Geneseeq Technology Inc. ("Geneseeq"), a precision oncology diagnostics company, and AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN), a global biopharmaceutical company, are excited to announce their strategic collaboration to establish a Bio-Diagnostic Innovation Center in Guangzhou, China.

• AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation Join the Access to Comprehensive Genomic Profiling Coalition

  4/19/2021

  The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NYSE: NVTA) to its coalition of companies advocating for appropriate coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer by U.S.

• Sanguina Announces Collaboration with AstraZeneca on Smartphone Application Study for Hemoglobin Management in Patients with Anemia of Chronic Kidney Disease (CKD)

  4/14/2021

  AnemoCheck Mobile is the first app of its kind to offer patients a remote screening option for anemia, without the need for a blood test

• AstraZeneca Announces Collaboration with Massachusetts General Hospital to Accelerate Digital Health Solutions

  4/6/2021

  AstraZeneca - Heart failure and asthma studies will pilot a new digital health platform to help improve outcomes for patients with chronic diseases

• Thrombosis Canada Statement on AstraZeneca Vaccine and Blood Clots

  3/12/2021

  There have been recent reports from Europe that the SARS-CoV-2 (COVID-19) vaccine made by AstraZeneca, which was recently approved for use in Canada, may be associated with thrombotic complications (blood clots).

• Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis

  2/17/2021

  Phase 3 OlympiA Trial Evaluated LYNPARZA in Germline BRCA -mutated High-Risk HER2-Negative Early-Stage Breast Cancer Following Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

• AliveCor Announces Collaboration with AstraZeneca to Develop Non-Invasive Potassium Monitoring Solutions

  2/16/2021

  AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced a new collaboration with AstraZeneca

• Matrix Medical Network Collaborates with AstraZeneca on Phase III Clinical Trial for COVID-19 Long-Acting Antibody Combination

  2/3/2021

  Matrix Medical Network Will Provide Mobile Health Clinics and Experienced Clinicians to Reach High Risk and Hard to Recruit Populations in AstraZeneca's Phase III STORM CHASER Prevention Trial in the US

• Statement on the European Medicines Agency's recommended authorization of the AstraZeneca COVID-19 vaccine

  1/29/2021

  Health Canada is aware that the European Medicines Agency has recommended granting a conditional marketing authorization for the COVID-19 vaccine manufactured by AstraZeneca and Oxford University.

• TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer

  1/29/2021

  TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer Data at WCLC showed patients in the practice-changing ADAURA Phase III trial maintained their quality of life based on patient-reported outcomes New data reinforce the ability of TAGRISSO to penetrate the blood-brain barrier in patients with central nervous system metastases

• CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia

  1/25/2021

  Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib. The trial also met a key secondary endpoin

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer

  1/18/2021

  AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

• AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer

  1/13/2021

  AstraZeneca will present new data from across the innovative lung cancer portfolio at the IASLC 2020 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer, 28 to 31 January 2021.

• GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

  1/11/2021

  GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect